IMV - IMV appoints Michael P. Bailey as Chairman of the board

IMV (NASDAQ:IMV) has appointed Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology as Chairman of the Board, effective May 1, 2022. Mr. Bailey has served on the company's Board of Directors since 2020 and chairs the governance committee, as well as serving as a member of the audit and clinical governance committees. Most recently, Mr. Bailey played a critical role in the approval of AVEO’s lead compound, FOTIVDA (tivozanib), a treatment targeting relapsed and refractory advanced renal cell carcinoma for patients who have failed at least two prior therapies.

For further details see:

IMV appoints Michael P. Bailey as Chairman of the board